In addition, for patients with high‐risk factors, EGFR or ALK‐EML4 fusion mutations, or PD‐L1 expression of >50% who undergo IGTA for early lung cancer, adjuvant chemotherapy/immunotherapy/TKI therapy to reduce recurrence and metastasis is likely to become one of the key research directions in the future. This evidence concerns the gene ALK and lung cancer.